XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborations with Third Parties              
Total Revenues         $ 75,475 $ 78,447  
Royalty Revenue From DSE And Sale Of Bulk Tablets              
Collaborations with Third Parties              
Total Revenues         18,200 9,900  
Collaboration Revenue              
Collaborations with Third Parties              
Total Revenues         19,612 38,400  
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement              
Collaborations with Third Parties              
Upfront cash payment     $ 150,000        
Cash payment to the Company             $ 150,000
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales     15.00%        
Daiichi Sankyo Europe GmbH ("DSE") | Collaborative Arrangement | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales     25.00%        
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities              
Collaborations with Third Parties              
Upfront cash payment   $ 60,000          
Potential additional future payments   $ 450,000          
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Collaboration Revenue              
Collaborations with Third Parties              
Total Revenues         600 0  
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales   15.00%          
Otsuka Pharmaceutical Co Ltd | Exclusive Developmental Activities | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales   30.00%          
Milestone payment, first JNDA submissions   $ 20,000          
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000          
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000          
Milestone payments related to total net sales achievements   $ 310,000          
Daiichi Sankyo Co. Ltd              
Collaborations with Third Parties              
Total Revenues           28,500  
Daiichi Sankyo Co. Ltd | Collaborative Arrangement              
Collaborations with Third Parties              
Total Revenues         $ 800 28,500  
Consideration cash payment $ 30,000            
Additional one time payment $ 175,000            
Remaining upfront payment           700  
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Minimum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales 5.00%            
Daiichi Sankyo Co. Ltd | Collaborative Arrangement | Maximum              
Collaborations with Third Parties              
Percentage of royalties to be received on the net sales 20.00%            
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, License To Intellectual Property              
Collaborations with Third Parties              
Total Revenues           28,000  
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, Ongoing Regulatory And Development Activities              
Collaborations with Third Parties              
Total Revenues           $ 500  
Serometrix | Collaborative Arrangement              
Collaborations with Third Parties              
Upfront cash payment       $ 12,500